Protalix BioTherapeutics Reports Positive Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease
September 21, 2018 10:57 ET
|
Protalix BioTherapeutics, Inc.
Preliminary Results Indicate Improvement in Kidney Function in Patients Switched from agalsidase alfa (Replagal®) to pegunigalsidase alfa (PRX-102) A deterioration trend in patients’ kidney...
Protalix BioTherapeutics to Present Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 1st Canadian Symposium on Lysosomal Diseases 2018
September 17, 2018 07:00 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization...
Protalix BioTherapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
August 23, 2018 07:00 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Aug. 23, 2018 (GLOBE NEWSWIRE) -- GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and...
Protalix BioTherapeutics Appoints David Granot to its Board of Directors
August 13, 2018 07:00 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American: PLX, TASE: PLX), announced today that the Company’s Board of Directors has appointed Mr. David...
Protalix BioTherapeutics Reports 2018 Second Quarter Results and Provides Corporate Update
August 09, 2018 07:00 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
Protalix BioTherapeutics to Hold Second Quarter 2018 Financial Results and Corporate Update Conference Call on August 9, 2018
July 31, 2018 07:00 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, July 31, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
Protalix BioTherapeutics Expands Partnership with Chiesi Farmaceutici to Include Exclusive U.S. Rights for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
July 24, 2018 07:00 ET
|
Protalix BioTherapeutics, Inc.
Protalix to receive $25 million upfront, an additional up to $20 million in development costs and an additional up to $760 million in potential regulatory and commercial milestone payments for the...
Protalix BioTherapeutics Announces Additional Positive Results from Final Analysis of the Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis
June 05, 2018 07:00 ET
|
Protalix BioTherapeutics, Inc.
Mucosal Improvement Observed in 61% of the Patients and 33% achieved Mucosal Healing Clinical Responses Observed in 67% of the Patients and Clinical Remission Observed in 28% of the Patients 89% of...
Protalix BioTherapeutics Announces Poster Presentation on Baseline Characteristics for Fabry Disease Patients Screened in the Phase III BALANCE Study of Pegunigalsidase Alfa at the 55th ERA-EDTA Congress
May 25, 2018 07:00 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, May 25, 2018 (GLOBE NEWSWIRE) -- GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and...
Protalix Announces Exchange and Discharge of Remaining 2018 Notes
May 24, 2018 07:00 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, May 24, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (the “Company”) (NYSE American:PLX) (TASE:PLX) announced today that $3.42 million of the aggregate principal amount...